Document is current
Any future updates will be listed below
-
Authors
Hu, Xi
Shi, Yuwei https://orcid.org/0000-0002-0366-5599
Cheng, Suk Hang https://orcid.org/0000-0002-2880-2289
Huang, Zhaoyang
Zhou, Ze
Shi, Xiaoyu
Zhang, Yi
Liu, Jing
Ma, Mary-Jane L.
Ding, Spencer C. https://orcid.org/0000-0002-7244-5995
Deng, Jiaen
Qiao, Rong
Peng, Wenlei
Choy, L. Y. Lois https://orcid.org/0000-0002-1746-9804
Yu, Stephanie C. Y.
Lam, W. K. Jacky https://orcid.org/0000-0001-8922-5609
Chan, K. C. Allen https://orcid.org/0000-0003-1780-1691
Li, Hongsheng
Jiang, Peiyong
Lo, Y. M. Dennis https://orcid.org/0000-0001-8746-0293
-
Funding
Funding for this research was provided by:
This study was supported by the Innovation and Technology Commission of the Hong Kong SAR Government (InnoHK Initiative).
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 27 March 2025
First Online: 14 April 2025
Competing interests
: K.C.A.C. and Y.M.D.L. hold equities in DRA, Take2, and Insighta. K.C.A.C. is a Director of DRA, Take2, and Insighta. P.J. holds equities in Illumina. P.J. is a Director of DRA, KingMed Future, and Take2. W.K.J.L. is a director of DRA. X.H., P.J., K.C.A.C., and Y.M.D.L. have filed a patent application based on this work, which has recently been licensed to Pacific Biosciences.
